Trials
1 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.”In the company’s words, NCT03833206 on ClinicalTrials.gov
- Tested for
- Major Depressive Disorder
- Main trialPhase 1/2
- “The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.”In the company’s words, NCT03833206 on ClinicalTrials.gov
- Other names
- Extract of Radix Polygalae · BLI-1005
Other drugs for Major Depressive Disorder
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- 28 Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 28 Feb 2028 | A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients | |
| Phase 2Completed | 12 Mar 2019 | A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder | |
| Phase 2Completed | 15 Jul 2020 | A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD) | |
| Phase 2Completed | 6 Dec 2023 | PDC-1421 Treatment in Adult Patients With ADHD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026